Conversely, the analysis by Cahn et al. [16] reinforces this concept from the SGLT2i perspective, demonstrating that the profound reduction in heart failure hospitalisations and cardiovascular death with dapagliflozin is not attenuated by concomitant GLP-1 RA use; in fact, a numerically greater benefit was observed in this subgroup. This evidence concerns the gene GLP1R and heart failure.